Summary
Mortality and morbidity of nosocomial pneumonia remain high. Successful treatment of pulmonary infections depends on several factors including type of infection, offending pathogen, status of host defences, and adequate choice of antibiotic therapy. The physician’s decision should aim at achieving antibiotic concentrations beyond the MIC at the site of infection.
Gram-negative bacilli, notably Pseudomonos aeruginosa, Klebsiella pneumoniae and Escherichia coli, remain the most frequent agents in nosocomial pneumonia.
Staphylococcus aureus and Streptococcus pneumoniae predominate among the Gram-positive cocci. Pneumocystis carinii predominates in immunocompromised patients.
Protected sample bronchoscopy associated with quantitative cultures of samples, and quantification of intracellular microorganisms in cells recovered by broncho-alveolar lavage are two promising procedures which might replace previous, more aggressive methods. Penetration of antibiotics into lung tissue depends on physicochemical properties of the drug and the degree of inflammation of lung tissue.
Quinolones, macrolides, tetracyclines and trimethoprim penetrate well into bronchial secretions. Penetration is moderate to low for aminoglycosides and β-lactams.
Fluoroquinolones and new β-lactam agents, including third-generation cephalosporins imipenem, aztreonam and ticarcillin-clavulanate, showed comparative clinical efficacy in treatment of nosocomial pneumonia, with an efficacy rate close to 80%. Aminoglycosides should not be used alone.
Combination therapy reduces but does not eliminate the risk of selection of Gram-negative resistant mutants. It should not be used routinely except for P. aeruginosa, Enterobacter cloacae and Serratia marcescens infections.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bakker-Vandenberg IAJM, Vandenberg JC, Michel MR. Therapeutic activities of cefazolin, cefotoxine, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rat. Antimicrobial Agents and Chemotherapy 22: 1042–1050, 1982
Bartlett JG, O’Keefe P, Tolly FP, Louie TJ, Gobach SL. Bacteriology of hospital-acquired pneumonia. Archives of Internal Medicine 146: 868–871, 1986
Bayer AS. Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 8: 1102–1110, 1989
Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. Journal of Antimicrobial Chemotherapy 8: 171–174, 1981
Berk SL, Verghese A. Emerging pathogens in nosocomial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 8: 11–14, 1989
Berk SL, Verghese A, Holtsclaw SA, Smith K. Enterococcal pneumonia: occurrence in patients receiving broad-spectrum antibiotic regimens and enterai feeding. American Journal of Medicine 74: 153–154, 1983
Berré J, Thys JP, Husson M, Diamon G, Klastersky J. Penetration of ciprofloxacin in bronchial secretions after intravenous administration. Journal of Antimicrobial Chemotherapy 22: 499–504, 1988
Boccazzi A, Langer M, Mandelli M, Ranzi AM, Urso R. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. Journal of Antimicrobial Chemotherapy 23: 401–407, 1989
Boden CR, Lampton LM, Miller DP, Tarka EF, Everett ED. Endobronchial pH: relevance to aminoglycoside activity in Gramnegative bacillary pneumonia. American Review of Respiratory Diseases 127: 39–41, 1983
Boon RJ, Pierce CV. Distribution of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid into infected pleural fluid-exudate of mice and effect of therapy. In Spits et al. (Eds) Proceedings of the 13th International Congress of Chemotherapy, pp. 4.1/6.9, H. Erdman, Wien, 1983
Brown RB, Kruse JA, Counts GW, Russel JA, Christou NV, et al. Double-blind study of endotracheal tobramycin in the treatment of Gram-negative bacterial pneumonia. Antimicrobial Agents and Chemotherapy 34: 269–272, 1990
Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, et al. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35: 373–447, 1988
Chastre J, Fagon JY, Soler P, Domart Y, Pierre J, et al. Quantification of BAL cells containing intracellular bacteria rapidly identifies ventilated patients with nosocomial pneumonia. Chest 95(Suppl.): 190–192, 1989b
Chastre J, Fagon J-Y, Domart Y, Gibert C. Diagnosis of nosocomial pneumonia in intensive care unit patients. European Journal of Clinical Microbiology and Infectious Diseases 8: 35–39, 1989a
Choisson RE, Slutkin G. Tuberculosis and human immunodeficiency virus infection. Journal of Infectious Diseases 159: 96–100, 1989
Cordonnier C, Bernaudin JF, Bierling P, Huet Y, Vernant JP. Pulmonary complications occurring after allogeneic bone marrow transplantation. Cancer 58: 1047–1054, 1986
Cox AL, Meewis JMJM, Horton R. Penetration into lung tissue after intravenous administration of amoxycillin/clavulanate. Journal of Antimicrobial Chemotherapy 24(Suppl. E): 87–91, 1989
Donowitz GR, Mandell GL. Acute pneumonia. In Mandell et al. (Eds) Principles and practice of infectious disease, 3rd edition, pp. 540–560, Churchill Livingstone, 1990
Donowitz GR, Mandell GL. Empiric therapy for pneumonia. Reviews of Infectious Diseases 5 (Suppl.): S40–S54, 1983
Dull WL, Alexander MR, Kasik JE. Bronchial secretion levels of amikacin. Antimicrobial Agents and Chemotherapy 16: 767–771, 1979
Ebden P, Nell P, Farrow PR. Sputum levels of fluconazole in humans. Antimicrobial Agents and Chemotherapy 33: 963–964, 1989
Erttmann M, Ullman U, Koch EM. Results of a clinical and pharmacokinetic study of ceftazidime in patients with postoperative pneumonia on assisted ventilation. Journal of Hospital Infection 15(Suppl. AP): 55–59, 1990
Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of protected specimen bush and quantitative culture techniques. American Review of Respiratory Diseases 139: 877–884, 1989
Follath F, Costo E, Thommen A, Frei R, Burdeske A, et al. Clinical consequences of development of resistance to third generation cephalosporins. European Journal of Clinical Microbiology 6: 446–450, 1987
Frasechini F, Scuglione F, Pintucci G, Maccarinnelli G, Dugnani S, et al. The diffusion of clarithromycin and roxithromycine into nasal mucosa, tonsil and lung in humans. Journal of Antimicrobial Chemotherapy 27(Suppl. A): 61–65, 1991
Gerson SL, Tolbot GH, Hurwitz S, Strom BL, Lusk E, et al. Prolonged granulocytonia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Annals of Internal Medicine 100: 345–351, 1984
Glatt AE, Chirgwin K, Landesman SH. Treatment of infections associated with human immunodeficiency virus. New England Journal of Medicine 318: 1439–1448, 1988
Gonzalez JP, Henwood JM. Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 37: 628–668, 1989
Grinan NP, Lucena FM, Romero JV, Michavila IA, Dominguez SU, et al. Yields of percutaneous needle lung aspiration in lung abscess. Chest 97: 69–74, 1990
Groeneveld K, van Alphen L, Eijk Paul P, Visschers G, Jansen HM, et al. Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment or persistence. Journal of Infectious Diseases 161: 512–517, 1990
Hager H, Verghese A, Alvarez S, Berk SL. Branhamella catarrhalis respiratory infections. Review of Infectious Diseases 9: 1140–1149, 1987
Harstein AI, Rashad AL, Liebler JM, Actis LA, Freeman J, et al. Multiple intensive care unit outbreak of Acinetobacter coleoacetiens, subspecies anitratus: respiratory infection and colonization associated with contaminated, reviable ventilator circuits and resuscitation bags. American Journal of Medicine 85: 624–631, 1988
Kemmerich B, Lode H. Rational use of new antibiotics in respiratory infections. In Pennington JE (Ed.) Respiratory infections: diagnosis and management, 2nd ed., pp. 648–657, Raven Press, New York, 1988
Klastersky J, Carpentier-Meunier F, Kahan-Coppens L, Thys JP. Endotracheally administered antibiotics for Gram-negative bronchopneumonia. Chest 75: 586–591, 1979
Klastersky J, Thys JP, Mombelli G. Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to Gram-negative bacteria. Review of Infectious Diseases 3: 74–83, 1981
Kugler JW, Armitage JO, Helms CM, Klassen LW, Goeken NE, et al. Nosocomial Legionnaires’ Disease: Occurrence in recipients of bone marrow transplants. American Journal of Medicine 74: 281–288, 1989
La Force FM. Systemic antimicrobial therapy of nosocomial pneumonia: Monotherapy versus combination therapy. European Journal of Clinical Microbiology and Infectious Diseases 8: 61–68, 1989
Lode H, Kemmerich B, Gzuhlke G, Dzwillo G, Koeppe P, et al. Cefotaxime in bronchopulmonary infections: a clinical and pharmacological study. Journal of Antimicrobial Chemotherapy 6: 193–198, 1980
Mangi RJ, Greco T, Ryan J, Thornton G, Andriole VT. Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia. American Journal of Medicine 84: 68–74, 1988
Marks MI, Prentice R, Swerson R, Cotton EK, Eichkoff TC. Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections. Journal of Pediatrics 79: 822–828, 1971
Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation: 5-year prospective study. Review of Infectious Diseases 11: 586–599, 1989
Martin C, Gouin F, Fourrier F, Junginger W, Prieur BL. Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients. Journal of Antimicrobial Chemotherapy 21: 795–799, 1988
Meyers JD. Infection in bone marrow transplant recipients. American Journal of Medicine 81(Suppl. 1A): 27–38, 1986
Miletovic D, Braveny I. Development of resistance during antibiotic therapy. European Journal of Clinical Microbiology 6: 234–244, 1987
Miliauskas JR, Webber BL. Disseminated varicella at autopsy in children with cancer. Cancer 53: 1518–1525, 1984
Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 33: 346–391, 1987
Moore RD, Smith C, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. American Journal of Medicine 77: 657–662, 1984
Morks MI. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. Journal of Pediatrics 98: 173–179, 1981
Muller-Serieys C, Bergogne-Berezin E, Rowan C, Dombret MC. Imipenem penetration into bronchial secretions. Journal of Antimicrobial Chemotherapy 20: 618–619, 1987
Nolen TM, Phillips HL, Hall HJ. Comparison of aztreonam and tobramycin in the treatment of LRTI caused by Gram-negative bacilli. Review of Infectious Diseases 7(Suppl. 4): 666–668, 1985
Pallares R, Gudiol F, Linares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. New England Journal of Medicine 317: 18–22, 1987
Peloquin Chuck A, Cumbo TJ, Sands MF, Schentog JJ. Intravenous ciprofloxacin for nosocomial LRTI. Review of Infectious Diseases 11(Suppl. 5): 1225–1226, 1989
Pennington JE, Block ER, Reynolds HY. 5-Fluorocytosine and amphotericin B in bronchial secretions. Antimicrobial Agents and Chemotherapy 6: 324–326, 1975
Pennington JE. Penetration of antibiotics into respiratory secretions. Reviews of Infectious Diseases 3: 67–73, 1981
Peterson LR. Animal models: the in-vitro evaluation of ciprofloxacin. Journal of Antimicrobial Chemotherapy 18(Suppl. D): 55–64, 1986
Phillips I, Warren C, Shannon K, King A, Hanslo D. In-vitro antibacterial activity and susceptibility of βr-lactamases compared with that of cefotaxime, moxalactam and other βr-lactam antibiotics. Journal of Antimicrobial Chemotherapy (Suppl. B): 23-31, 1981
Pulverer G, Peters G, Kunstman G. In vitro activity of ticarcillin with and without clavulanic acid against isolate of gram-positive and gram-negative bacteria. Journal of Antimicrobial Chemotherapy 17(Suppl.): 1–5, 1986
Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia. Annals of Internal Medicine 97: 813–820, 1982
Rubin RH, Greene R. Etiology and management of the compromised patient with fever and pulmonary infiltrates. In Rubin RH, Young LS (Eds) Clinical approach to infection in the compromised host, pp. 131–163, Plenum, New York and London, 1988
Saito A, Sowatari K, Fukuda Y, Nogasawa M, Koga H, et al. Susceptibility of Legionella pneumophila to pefloxacin in vitro and in experimental Legionella pneumophila in guinea pigs. Antimicrobial Agents and Chemotherapy 28: 15–20, 1985
Salato RA, Gebhart RL, Palmer PL, Wade BH, Scheid WM, et al. Pneumonia treated imipenem/cilastin. American Journal of Medicine 78(Suppl. 6A): 204–209, 1985
Schwigon CD, Mulla FW, Schulze B, Maslak A. Timentin in the treatment of nosocomial bronchopulmonary infections in intensive care units. Journal of Antimicrobial Chemotherapy 17(Suppl. C): 115–122, 1986
Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine 135: 715–719, 1975
Simon HB. Mycobacterial and nocardial infections in the compromised host. In Rubin RM, Young LS (Eds) Clinical approach to infection in the compromized host, pp. 221–251, Plenum, New York and London, 1988
Singer C, Armstrong D, Rosen PP, Walzer PD, Yu V. Diffuse pulmonary infiltrates in immunosuppressed patients. American Journal of Medicine 66: 110–120, 1979
Slevin NJ, Aitken J, Thornley PE. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections. Lancet 1: 782–789, 1984
Swabb EA, Jenkins SA, Muir JG. Summary of worldwide clinical trials of aztreonam, with LRTI. Review of Infectious Diseases 7(Suppl. 4): 772–777, 1985
Thadepalli M. Lower respiratory tract. In Ristuccia AM & Curha BA (Eds) Antimicrobial therapy, pp. 489, 454, Raven Press, New York, 1984
Thys JP, Husson M, Mombelli G, Klastersky J. Inactivation of netilmicin and amikacin by leukocytes. Abstract 353. In Proceedings of the Second Congress of Chemotherapy, Nice, 1980
Thys JP, Jacobs F, Motte S. Quinolones in the treatment of lower respiratory tract infections. Reviews of Infectious Diseases 11: S1212–S1219, 1989
Verghese A, Berk SL, Boelen L, Smith K. Group B streptococcal pneumonia in the elderly. Archives of Internal Medicine 142: 1642–1645, 1982
Vuye A, Pijck J. In-vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrobial Agents and Chemotherapy 27: 574–577, 1985
Wolfson JS, Hooper DC. Fluoroquinolones antimicrobial agents. Clinical Microbiology Reviews 2: 378–424, 1989
Wong GA, Peirce TH, Goldstein E, Hoeprich PD. Penetration of antimicrobial agents into bronchial secretions. American Journal of Medicine 59: 219–223, 1975
Woo AH, Yu VL, Goetz A. Potential in hospital modes of transmission of Legionella pneumophilia. American Journal of Medicine 80: 567–573, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aoun, M., Klastersky, J. Drug Treatment of Pneumonia in the Hospital. Drugs 42, 962–973 (1991). https://doi.org/10.2165/00003495-199142060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199142060-00005